Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Fulgent Genetics (NASDAQ:FLGT) Chief Scientific Officer, Hanlin Gao, sold 1,063 shares of common stock on September 3, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed at a weighted average price of $22.0267, resulting in a total transaction value of $23,414. Prices for the shares sold ranged from $21.92 to $22.175. The transaction comes as FLGT shares trade near their 52-week high, having surged 44% over the past six months. According to InvestingPro analysis, the stock currently appears undervalued.
Following the transaction, Gao directly owns 957,085 shares of Fulgent Genetics. The sale was to cover tax obligations related to the vesting of restricted stock units. InvestingPro data shows the company maintains a strong financial position with more cash than debt on its balance sheet, while management has been actively buying back shares. Discover 8 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Fulgent Genetics reported its Q2 2025 earnings, revealing a revenue of $81.8 million, which exceeded the forecast of $76.21 million. Despite this revenue beat, the company reported an earnings per share (EPS) of $0.07, falling short of the projected EPS of $-0.18. This resulted in a surprise of -138.89%. Additionally, UBS has upgraded Fulgent Genetics’ stock rating from Neutral to Buy, raising the price target from $20.00 to $30.00. The investment bank highlighted potential growth in Fulgent’s Precision Diagnostics segment, which accounts for about 60% of its total sales. UBS pointed to opportunities for market share gains due to a more favorable reimbursement landscape. These developments reflect the ongoing changes and potential growth in Fulgent Genetics’ business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.